insiderwall
Menu
SuperinvestorInsider
Zymeworks Inc. ZYME

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Zymeworks Inc. is a biotechnology company that focuses on innovating biotherapeutics for the treatment of cancer and autoimmune diseases. The company's core mission revolves around developing novel, multifunctional therapeutics with the potential to improve efficacy and reduce side effects compared to conventional canc

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees243
TickerZYME

Statistics

Market Cap$1.70B
Revenue (TTM)$106.0M
Net Income-$81.1M
Net Margin-76.6%
EPS$-1.08
P/E3.79
P/S20.79
P/B6.38
EV/EBITDA-12.26
ROE-42.0%
Dividend Yield
Price$23.07

Data: Twelve Data · Revenue = mcap / P/S